Buy these outperforming stocks with room to run, says UBS
As earnings season winds down, investors should be on the lookout for some stocks that might still have room for upside, according to UBS. Stocks rallied on Friday , spurred by Federal Reserve Chair Jerome Powell’s comments in Jackson Hole, Wyo. that suggested the central bank may begin adjusting its policy stance . Even with those gains, UBS has identified certain names that have already outperformed the market but still might have more upside potential, as “based on supportive valuations and [cash flow return on investment] momentum,” analyst Jenny Huang wrote in a Thursday note. She screened for stocks that met several criteria, including: Price return relative to the market over the past 13 weeks is more than 5% Cash flow return on investment revisions over the past 13 weeks is more than zero When splitting up the identified names by sectors, the analyst found that financials led the way with 22%, followed by industrials at 20% and information technology at 16%. Here are some of the names that popped up. Broadcom has outperformed the broader market in recent months, rising nearly 28% in the last three and almost 35% in the past six. That’s compared to the S & P 500’s rise of almost 11% and more than 7% in those timeframes, respectively. AVGO 6M mountain AVGO, 6-month The chipmaker’s price return relative to the market in the last 13 weeks is 25.4%, UBS found. A majority of analysts on Wall Street are bullish on the name as well, with 41 out of 43 total analysts having a strong buy or buy rating on it, per LSEG. Piper Sandler is among those, reiterating its overweight rating on Friday. Its $315 price target also implies 7% upside potential from Friday’s close. Anglo-Swedish biotech firm AstraZeneca has outperformed the broader market this year, with U.S.-listed shares gaining more than 23% versus the S & P 500’s nearly 10% advance in 2025. Not only that, Huang noted that the stock’s nearly 15% gain in the last month has outpaced its European pharmaceutical peers. Additionally, AstraZeneca’s price return relative to the market in the last 13 weeks is 6.8%. Moreover, with most analysts covering it having an optimistic view of the stock, the LSEG consensus target of almost $101 reflects nearly 25% upside ahead. PepsiCo also made the list, having a price return relative to the market over the past 13 weeks at 5.4%. While the stock is negative on the year, it’s risen 15% in the past three months, outperforming the broader market.
<
